Research programme: serotonin reuptake inhibitors - Sosei R&D

Drug Profile

Research programme: serotonin reuptake inhibitors - Sosei R&D

Alternative Names: ARAK0029; ARAK0051; SD 726

Latest Information Update: 23 Aug 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sosei R&D
  • Class Benzoxazines; Small molecules
  • Mechanism of Action Adrenergic receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Back pain; Pain

Most Recent Events

  • 30 Aug 2005 Arakis has been acquired by Sosei
  • 29 Mar 2005 Preclinical trials in Pain in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top